The boss of the drugs giant behind Ozempic has quit after falling behind in the global race to develop weight-loss medication ...

It’s the end of an era at Novo Nordisk as longtime CEO Lars Fruergaard Jørgensen—who recently shepherded the company through ...

Novo Nordisk said Jørgensen will remain in his role temporarily to ensure a “smooth transition” while a search for his ...

Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

While M&A activity slowed in the first quarter of 2025, including in life sciences, there have been plenty of noteworthy developments in the ...

Experts say more research needs to be done to understand what drove the reduction, but they mention several possible factors.

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Lake Forest Hospital, joins John Williams to talk about ...

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...